Abstract:Abstract Background/Aims This audit aimed to improve the standard of prescribing JAK inhibitors and to determine the sustainability of response in Rheumatology patients at Royal Berkshire hospital (RBH) in Reading. During the last decade Janus kinase (JAK) inhibitors have had a dramatic uptake across multiple conditions in Rheumatology to control inflammation, reduce damage, pain and fatigue. Emerging data provides insight into their safety and effectiveness. These medications are contraindicated in patients with serious infections, cancer, blood clots, pregnancy and abnormal liver or renal function. Prescribing these medications needs careful consideration. We want to ensure we are taking appropriate precautions to minimize them and to review their efficacy in a real world District General Hospital setting. Methods Data was collected retrospectively from 100 patients who started treatment with JAK inhibitors in the last five years. We reviewed the indication, stage of disease, risk factors, whether patient information was provided and the response to treatment. We included patients with Rheumatoid arthritis (RA), Ankylosing Spondylitis, Psoriatic Arthritis. Our data collection template covered demographic information, medical history and disease activity at baseline as well as after starting JAK inhibitors; concomitant use of other DMARDs, safety and efficacy. Results A cohort of 100 patients (69 female and 31 male, average age 51.4 years) diagnosed with rheumatic conditions. The largest group were started on Baricitinib 64%, the smallest group on Upadacitinib. Baricitinib was the first JAK inhibitor approved for use in Rheumatology. Most RA patients were seropositive and had active disease at baseline. Comorbidities such as hypertension and diabetes were noted in 24 % and 14% of the patients respectively. 31% had a past history of smoking history, 9% had a history of malignancy. 22% of patients were on JAK monotherapy, the majority required an additional disease modifying antirheumatic drug (DMARDs). 43% of patients had tried two to three different biologics before starting JAK inhibitors. The average time from diagnosis to the first use of JAK inhibitors was 11 years. 2% of patients developed MACE and 3% herpes zoster on JAK. Only one of the deceased patients was on JAK inhibitors at the time of death and no causality was found. In < 10% of patients discussion on potential side effects was documented at baseline. 36% have discontinued the medication. Conclusion JAK inhibitors are highly effective in a real world population even when started after two to three biologic failures. A significant reduction in disease activity and sustainable remission was obtained in 64% of our patients. 43% of patients had previously failed to two or three biologics before starting a JAK inhibitor. We could improve patient education before starting treatment. Disclosure A. Escudero: None. S. Jain: None. N. Nisoe: None. J. McNally: None. H. Wardak: None.

Results of a Retrospective, Multicenter Cohort Study

Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study

Incidence of serious infections in the working-age Japanese adult population with rheumatoid arthritis treated with tumor necrosis factor-α inhibitors and interleukin-6 inhibitors: A nationwide retrospective cohort study

Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry

Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study

Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea

Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs

Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry

Infection risk with JAK inhibitors in dermatoses: a meta‐analysis

Real-World Experience With Janus Kinase Inhibitors in Immune-Mediated Diseases: Clinical Experience of a University Hospital

Increased Risk of Herpes Zoster in Rheumatoid Arthritis Not Only Due to JAK Inhibitors—Study of 392 Patients from Single University Center

Long-term adverse event risks of oral JAK inhibitors versus immunomodulators: a literature review

JAK-inhibitors and risk on serious viral infection, venous thromboembolism and cardiac events in patients with rheumatoid arthritis: A protocol for a prevalent new-user cohort study using the Danish nationwide DANBIO register

Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor

P008 High response rate to Janus Kinase inhibitors after multiple biologic drug failures, across disease indications, in a District General Hospital: results from an audit of the prescribing, safety and efficacy of Janus Kinase inhibitor

Incidences and risk factors of serious infections among different rheumatic patients: a retrospective cohort study

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register

Trends in risks of malignancies in Japanese patients with rheumatoid arthritis: Analyses from a 14-year observation of the IORRA cohort